Scilex Holding Company (SCLXW)

USD 0.21

(-23.88%)

Net Debt Summary of Scilex Holding Company

Scilex Holding Company's latest annual net debt in 2023 was 124.54 Million USD , up 16190.7% from previous year.
Scilex Holding Company's latest quarterly net debt in 2024 Q1 was 110.22 Million USD , down -11.49% from previous quarter.
Scilex Holding Company reported annual net debt of -774 Thousand USD in 2022, down -100.51% from previous year.
Scilex Holding Company reported annual net debt of 150.4 Million USD in 2021, up 12.42% from previous year.
Scilex Holding Company reported quarterly net debt of 100.1 Million USD for 2024 Q2, down -9.18% from previous quarter.
Scilex Holding Company reported quarterly net debt of 5.76 Million USD for 2023 Q1, up 844.83% from previous quarter.

Annual Net Debt Chart of Scilex Holding Company (2023 - 2020)

Historical Annual Net Debt of Scilex Holding Company (2023 - 2020)

Year	Net Debt	Net Debt Growth
2023	124.54 Million USD	16190.7%
2022	-774 Thousand USD	-100.51%
2021	150.4 Million USD	12.42%
2020	133.78 Million USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	110.22 Million USD	-11.49%
2024 Q2	100.1 Million USD	-9.18%
2023 Q1	5.76 Million USD	844.83%
2023 Q3	123.38 Million USD	3323.67%
2023 FY	124.54 Million USD	16190.7%
2023 Q4	124.54 Million USD	0.93%
2023 Q2	3.6 Million USD	-37.48%
2022 FY	-774 Thousand USD	-100.51%
2022 Q2	3.68 Million USD	94.01%
2022 Q3	108.92 Million USD	2857.77%
2022 Q4	-774 Thousand USD	-100.71%
2022 Q1	1.89 Million USD	7747.25%
2021 Q2	38.01 Million USD	0.15%
2021 Q1	37.95 Million USD	15.28%
2021 Q3	38.15 Million USD	0.37%
2021 FY	150.4 Million USD	12.42%
2021 Q4	-24.82 Thousand USD	-100.07%
2020 Q3	32.92 Million USD	0.0%
2020 Q4	32.92 Million USD	0.0%
2020 FY	133.78 Million USD	0.0%
2020 Q2	32.92 Million USD	0.0%
2020 Q1	32.92 Million USD	0.0%

Peer Net Debt Comparison of Scilex Holding Company

Name	Net Debt	Net Debt Difference
Amgen Inc.	53.66 Billion USD	99.768%
AstraZeneca PLC	22.78 Billion USD	99.453%
Biogen Inc.	6.28 Billion USD	98.019%
Gilead Sciences, Inc.	18.9 Billion USD	99.341%
MIRA Pharmaceuticals, Inc.	-4.59 Million USD	2808.904%
Scilex Holding Company	124.54 Million USD	0.0%